CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
High ImpactOriginal article

Cerevance’s novel Parkinson’s drug nets a Phase III win  

Phase 3positivesolengeprasPositive
AI Analysis

Summary

Cerevance's solengepras achieved a Phase III win in Parkinson's disease. The company plans to determine next steps towards potential FDA approval.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III trial met primary endpoint

Importance:8/10
Sentiment:
0.85
Parkinson's diseasePhase IIIclinical trialneurology
Related Companies

Read the original article

Published by Clinical Trials Arena on October 7, 2026 1:28 PM

Read Original